Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis

Next Previous
X
Search
Trial Profile

A phase 2, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2007

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Bacterial infections; Chronic sinusitis
  • Focus Therapeutic Use
  • Sponsors Naryx Pharma

    • Most Recent Events

    • 27 Nov 2007 Patient enrolment completed.
    • 26 Nov 2007 Results expected after unblinding of data in first quarter of 2008.
    • 26 Nov 2007 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top